Agenus is advancing investigational immunotherapies designed to harness the immune system’s ability to recognize and fight cancer.
This showcase, developed for oncologists and other healthcare professionals, brings together research on botensilimab plus balstilimab (BOT+BAL). Explore the research summaries below to learn about the scientific rationale for BOT+BAL, the clinical evidence supporting its development in advanced and earlier-stage disease, and the planned ROBBIN Phase 3 neoadjuvant trial of BOT+BAL treatment in high-risk, non-metastatic MSS colon cancer or visit Agenus at www.agenusbio.com.
